Apexigen is a clinical stage biotech company developing immune checkpoint activators for oncology. The Company’s wholly-owned lead product candidate, APX005M, is a CD40 targeting immune checkpoint activator. With over 300 cancer patients enrolled in its clinical trials, APX005M has demonstrated efficacy activity in the neoadjuvant, first-line and post-PD-1/PD-L1 settings; in both PD-1 positive and negative patients; and in multiple tumor types. Apexigen’s preliminary Phase 1b data in first-line pancreatic cancer showing robust response and disease control rates and long duration of treatment for APX005M plus chemo with and without nivo was well received at 2019 AACR. APX005M has demonstrated synergistic activity with checkpoint inhibitors, chemotherapy, and chemoradiation and a favorable safety profile. APX005M is currently being evaluated in seven Phase 1b and Phase 2 clinical trials in multiple solid tumors including pancreatic cancer, esophageal and gastroesophageal junction cancers, NSCLC, metastatic melanoma and sarcoma. Apexigen has global rights to APX005M and a robust preclinical pipeline. In addition to APX005M, Apexigen's monoclonal antibody generation platform has generated multiple 6 clinical-stage programs that are now licensed to partners, the most advanced of which is under FDA evaluation for BLA approval.
75 Shoreway Road
San Carlos, CA 94070
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout Management Access: SF 2020
San Francisco, CA, United States,
January 13 –
January 16, 2020